Related Experiment Video
Updated: Jun 3, 2025
06:03
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
184
The Intricate Relationship Between Pulmonary Fibrosis and Thrombotic Pathology: A Narrative Review
Giovanni Cenerini1, Davide Chimera1, Marta Pagnini2
1UO Pneumologia, Azienda Ospedaliero-Universitaria Pisana, 56124 Pisa, Italy.
Cells
|January 8, 2025
Summary
Idiopathic pulmonary fibrosis (IPF) increases thrombosis risk. Extracellular vesicles (EVs) link fibrosis and coagulation, offering new therapeutic targets for managing this complex relationship.
Area of Science:
- Pulmonary Medicine
- Hematology
- Cell Biology
Background:
- Idiopathic pulmonary fibrosis (IPF) is linked to higher rates of thrombotic events and mortality.
- A complex, bidirectional relationship exists between pulmonary fibrosis and thrombosis.
- Extracellular vesicles (EVs) are increasingly recognized as key mediators in interstitial lung diseases (ILDs).
Purpose of the Study:
- To review the epidemiological evidence, pathogenetic mechanisms, and therapeutic strategies concerning the interplay between pulmonary fibrosis and thrombosis.
- To highlight the role of extracellular vesicles (EVs) in linking fibrosis and coagulation.
- To discuss emerging therapeutic implications and future research directions.
Main Methods:
- Literature review of epidemiological studies, pathogenetic mechanisms, and clinical trials.
- Focus on the role of coagulation factors, thrombotic pathways, and extracellular vesicles (EVs).
- Analysis of preclinical and early clinical data for novel therapeutic agents and EV-based approaches.
Main Results:
- Coagulation factors promote fibrosis, while fibrosis activates thrombotic pathways.
- Retrospective studies suggest anticoagulant benefits in IPF, though prospective trials face challenges.
- EVs act as crucial mediators in ILDs, contributing to both fibrosis and coagulation.
Conclusions:
- EVs are central to the pathogenesis of ILDs, linking fibrosis and thrombosis.
- Therapeutic strategies targeting EVs, novel anticoagulants, and profibrinolytic agents show promise.
- Further research is needed to optimize treatments, identify biomarkers, and understand EV roles in ILDs.
Keywords:
anticoagulantscoagulationextracellular vesiclesidiopathic pulmonary fibrosismortalitythrombosisMore Related Videos
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
150
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
150
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.7K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.7K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.7K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607
01:20COPD: Pathogenesis and Clinical Features
230
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
230
01:29Pneumonia II: Pathophysiology
212
The pathophysiology of pneumonia involves the following steps:
212